Origin Therapeutics Launches Investment Issuer Focused On Psychedelics-Related Startups

On July 27, 2021, Origin Therapeutics Holdings Inc. launched operations as an investment issuer focused on psychedelics-related companies. Origin Therapeutics is focused on identifying private, early-stage companies including early-stage drug development companies, clinics, as well as ancillary companies focused on education, marketing, and building awareness around the psychedelics industry.

The company has successfully raised 6.5 million for investments, general working capital, and listing on a publicly traded stock exchange. The founding share holders and board of directors are founders and/or early investors in Charlotte’s Web, MedReleaf, The flowr Corporation, Terrace Global, Cybin, bedrocan, Green . . .